APAntimo Papa

Antimo Papa

*This is an algorithmically generated author record based on publicly available information.

Antimo Papa has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical assessment of endothelial function in convalescent COVID-19 patients: a meta-analysis with meta-regressions

    by Pasquale Ambrosino, Stefano Sanduzzi Zamparelli, Marco Mosella, Roberto Formisano, Antonio Molino, Giorgio Alfredo Spedicato, Antimo Papa, Andrea Motta, Matteo Nicola Dario Di Minno, Mauro Maniscalco

    Endothelial dysfunction has been proposed to play a key role in the pathogenesis of coronavirus disease 2019 (COVID-19) and its post-acute sequelae. Flow-mediated dilation (FMD) is recognized as an...


  • Cognitive impairment and endothelial dysfunction in convalescent COVID‐19 patients undergoing rehabilitation

    by Pasquale Moretta, Mauro Maniscalco, Antimo Papa, Anna Lanzillo, Luigi Trojano, Pasquale Ambrosino


  • Open Access

    Clinical assessment of endothelial function in heart failure with preserved ejection fraction: A meta‐analysis with meta‐regressions

    by Pasquale Ambrosino, Antimo Papa, Agostino Buonauro, Marco Mosella, Ilenia Calcaterra, Giorgio Alfredo Spedicato, Mauro Maniscalco, Matteo Nicola Dario Di Minno

    Background: Endothelial dysfunction is a key mechanism in the development of cardiac remodelling and diastolic dysfunction in heart failure with preserved ejection fraction (HFpEF). Flow‐mediated (FMD) and nitrate‐mediated dilation (NMD) are noninvasive methods to assess endothelial function. We performed a meta‐analysis evaluating the impact of HFpEF on FMD and NMD.Methods: PubMed, Web of Science, Scopus and EMBASE databases were systematically searched according to Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Differences were expressed as mean difference (MD) with 95% confidence intervals (95%CI). The random effects method was used.Results: A total of seven studies were included in the final analysis, 7 with data on FMD (326 HFpEF patients and 417 controls) and 3 on NMD (185 HFpEF patients and 271 controls). Compared to controls, HFpEF patients showed significantly lower FMD (MD: −1.929; 95%CI: −2.770, −1.088;P < .0001) and NMD values (MD: −2.795; 95%CI: −3.876, −1.715;P < .0001). Sensitivity analyses substantially confirmed results. Meta‐regression models showed that increasing differences in E/A ratio (Z‐score: −2.002;P = .045), E/E’ ratio (Z‐score: −2.181;P = .029) and left atrial diameter (Z‐score: −1.951;P = .050) were linked to higher differences in FMD values between cases and controls.Conclusions: Impaired endothelial function can be documented in HFpEF, with the possibility of a direct association between the severity of diastolic and endothelial dysfunction. Targeting endothelial dysfunction through pharmacological and rehabilitation strategies may represent an attractive therapeutic option.


  • Open Access

    Performance of fractional exhaled nitric oxide in predicting response to inhaled corticosteroids in chronic cough: a meta-analysis

    by Pasquale Ambrosino, Mariasofia Accardo, Marco Mosella, Antimo Papa, Salvatore Fuschillo, Giorgio Alfredo Spedicato, Andrea Motta, Mauro Maniscalco

    Background. Chronic cough is a disabling condition with a high proportion of diagnostic and therapeutic failures. Fractional exhaled nitric oxide (FeNO) has been considered a useful biomarker for predicting inhaled corticosteroids (ICS) response. We evaluated the relationship between FeNO and ICS response in chronic cough by performing a systematic review with meta-analysis. Methods. PubMed, Web of Science, Scopus and EMBASE databases were systematically searched. Differences were expressed as Odds Ratio (OR) with 95% confidence intervals (95%CI). Pooled sensitivity, specificity, positive (PLR) and negative likelihood ratio (NLR), and area under the hierarchical summary receiver operating characteristic curve (HSROCAUC) were estimated. Results. Nine articles on 740 chronic-cough patients showed that the response rate to ICS was 87.4% (95%CI: 83.8–91.0) in 317 patients with a high FeNO and 46.3% (95%CI: 41.6–51.0) in 423 controls, with an attributable proportion of 47.0% and a diagnostic OR of 9.1 (95%CI: 3.7–22.4, p < .001). The pooled estimate of diagnostic indexes resulted in a sensitivity of 68.5% (95%CI: 46.7–84.4) and specificity of 81.9% (95%CI: 63.0–92.3), with a HSROCAUC of 0.82 (95%CI: 0.64–0.90). In a realistic scenario with a pre-test probability set at 30%, based on a pooled PLR of 3.79 (95%CI: 1.24–7.47) and NLR of 0.38 (95%CI: 0.22–0.66), the post-test probability was 62% with a high FeNO and 14% if the test was negative. Subgroup analyses confirmed a better performance for the recommended FeNO cut-off greater than 25 ppb. Meta-regression and sensitivity analyses showed no impact of major demographic and clinic variables on results. Conclusions. A high FeNO before starting ICS therapy may help identify chronic-cough patients responding to treatment, with a better performance ofhigher cut-off values. Further studies are needed to evaluate the real usefulness of this biomarker to guide cough therapy and optimise strategies in different healthcare settings (community, hospital, rehabilitation).


  • A Randomized, Double-Blind Comparison of Lercanidipine 10 and 20 mg in Patients with Stable Effort Angina

    by Domenico Acanfora, Mihai Gheorghiade, Luigi Trojano, Giuseppe Furgi, Antimo Papa, Francesco Cacciatore, Luisa Viati, Francesca Mazzella, Franco Rengo

    We evaluated the antiischemic action and the effects on left ventricular response to exercise of lercanidipine, a long-acting dihydropyridine calcium antagonist, in 23 patients with stable effort angina in a randomized, double-blind, parallel trial. Left ventricular function was assessed during upright bicycle exercise using an ambulatory radionuclide detector for continuous noninvasive monitoring of cardiac function. Exercise was performed under control conditions before (run-in placebo period) and after 2-week treatment with lercanidipine 10 or 20 mg once daily. During the placebo run-in period and at the study end, patients underwent clinical examination, ECG, exercise tests, ambulatory ventricular scintigraphic monitoring (VEST). Results showed that both drug doses increased time to onset of ST segment depression >/=1 mm and peak ST segment depression, with improvement of total exercise duration. Heart rate, blood pressure, and the rate-pressure product did not significantly change with respect to pretreatment value. The left ventricular ejection fraction, indicating contractility state of myocardium, was unchanged at rest and during exercise after both lercanidipine doses. In conclusion, lercanidipine is safe and effective in reducing ischemia in patients with stable effort angina without any deterioration of cardiac function.


  • A Randomized, Double-Blind Comparison of 10 and 20 mg Lercanidipine in Patients With Stable Effort Angina: Effects on Myocardial Ischemia and Heart Rate Variability

    by Domenico Acanfora, Luigi Trojano, Mihai Gheorghiade, Costantino Picone, Antimo Papa, Giuseppe Furgi, Franca Giuliano, Roberto Maestri, Franco Rengo

    We evaluated the anti-ischemic action and the effects on autonomic function of lercanidipine, a long-acting dihydropyridine calcium antagonist, in 25 patients with stable effort angina in a randomized, double-blind, parallel trial. After a 2-week placebo run-in period, patients entered a 2-week treatment period with 10 or 20 mg of lercanidipine once daily. During the placebo run-in period and at the study end, the patients underwent clinical examination, electrocardiography, exercise tests, 24-hour Holter electrocardiography for long-term heart rate variability evaluation, and short-term spectral analysis of heart rate and systolic blood pressure variability and plasma epinephrine and norepinephrine levels at rest and during tilting. Results showed that time to onset of ST segment depression ≥1 mm was significantly increased by both drug doses. No significant change was recorded in the average hourly heart rate after treatment with both 10 and 20 mg of lercanidipine. During the 24-hour recordings, no significant change was observed in low-frequency power, high-frequency power, or low frequency/high frequency. In the standing position, there was a significant increase in plasma norepinephrine and epinephrine concentration in both groups, and no change in the supine position after 10 and 20 mg of lercanidipine. When considering short-term heart rate variability, no significant difference was observed in either treatment group in low frequency, high frequency, or their ratio on electrocardiographic R-R spectra. The blood pressure spectral component was also unchanged. In conclusion, lercanidipine is effective in reducing ischemia in patients with stable effort angina. Moreover, lercanidipine does not cause adrenergic activation, which is the main mechanism hypothesized to explain the negative effect on cardiovascular mortality assigned to short-acting dihydropyridine calcium antagonists.


  • Relative lymphocyte count: A prognostic indicator of mortality in elderly patients with congestive heart failure

    by Domenico Acanfora, Mihai Gheorghiade, Luigi Trojano, Giuseppe Furgi, Evasio Pasini, Costantino Picone, Antimo Papa, Gian Luca Iannuzzi, Robert O. Bonow, Franco Rengo


  • Randomized, placebo-controlled, crossover, double-blind comparison of immediate- and sustained-release formulations of Gallopamil in elderly patients with stable effort angina

    by Domenico Acanfora, Gian Domenico Pinna, Luigi Trojano, Giuseppe Rengo, Giuseppe Furgi, Antimo Papa, Costantino Picone, Luigi Odierna, Antonio Nicolino, Franco Rengo

  • Acute dose-response, double-blind, placebo-controlled pilot study of lercanidipine in patients with angina pectoris

    by Domenico Acanfora, Mihai Gheorghiade, Domenico Rotiroti, Luigi Trojano, Giuseppe Rengo, Giuseppe Furgi, Antimo Papa, Costantino Picone, Antonio Nicolino, Luigi Odierna, et al.


  • Open Access

    "Warm-Up" Phenomenon in Adult and Elderly Patients With Coronary Artery Disease: Further Evidence of the Loss of "Ischemic Preconditioning" in the Aging Heart

    by Giancarlo Longobardi, Pasquale Abete, Nicola Ferrara, Antimo Papa, Renato Rosiello, Giuseppe Furgi, Claudio Calabrese, Francesco Cacciatore, Franco Rengo

    Background. A reduction of exercise-induced ischemia in patients with coronary artery disease by means of brief period of exercise followed by resting is called the “warm-up” phenomenon. This phenomenon may represent a clinical counterpart of “ischemic preconditioning.” We studied the warm-up phenomenon in both adult and elderly patients with similar angiographic evidence of coronary artery disease, using three exercise tests after excluding the “training effect.” Methods. In order to verify the presence of “training effect,” three exercise tests were performed in days 1, 2, and 3 (“training” tests). The third test was used as baseline for a successive test, performed after a recovery period of 10 minutes to reestablish baseline electrocardiographic conditions. A third exercise test was performed 30 minutes later (“warm-up” tests). Results. “Training” tests did not differ in all parameters in both adult and elderly patients. “Warm-up” tests showed that time to onset 1-mm ST depression was significantly higher (p < .001), whereas ST depression and time to recovery was significantly lower in the second and third test in adult but not in elderly patients ( p < .001). Difference (in seconds) in the time at which 1-mm ST depression occurred on first warm-up exercise compared with the second was inversely correlated with age (p < .001). Conclusions. Previous exercise followed by resting is able to reduce the successive exercise-induced ischemia (“warm-up” phenomenon) in adult but not in elderly patients with coronary artery disease. This is independent of a greater age-related severity of coronary disease and of “training effect.” These results confirm the hypothetical age-related reduction of “ischemic preconditioning” in aging heart.